Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Tanja Fens, Guiling Zhou, Maarten J. Postma, Eugène P. van Puijenbroek & Job F.M. van Boven. (2021) Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed?. Expert Opinion on Pharmacotherapy 22:7, pages 923-935.
Read now
Read now
Mafalda Ramos, Mark Lamotte, Laetitia Gerlier, Per Svangren, Anna Miquel-Cases & John Haughney. (2019) Cost-effectiveness of physical activity in the management of COPD patients in the UK. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 227-239.
Read now
Read now
Mario Malerba, Alessandro Radaeli, Giuseppe Santini, Jaymin Morjaria, Nadia Mores, Chiara Mondino, Giuseppe Macis & Paolo Montuschi. (2018) The discovery and development of aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Drug Discovery 13:6, pages 563-577.
Read now
Read now
Jose Luis Lopez-Campos, Carmen Calero-Acuña, Eduardo Márquez-Martín, Esther Quintana Gallego, Laura Carrasco-Hernández, Maria Abad Arranz & Francisco Ortega Ruiz. (2017) Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 1867-1876.
Read now
Read now
Articles from other publishers (7)
Jia Liu, Xiaoning He & Jing Wu. (2022) Economic Evaluation of Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate for the Treatment of Moderate to Very Severe Chronic Obstructive Pulmonary Disease in China Using a Semi-Markov Model. Applied Health Economics and Health Policy 20:5, pages 743-755.
Crossref
Crossref
Shuli Qu, Xuedan You, Tianyi Liu, Lijiao Wang, Zheng Yin, Yanjun Liu, Chong Ye, Ting Yang, Mao Huang, Hongchao Li, Liwen Fang & Jinping Zheng. (2021) Cost-effectiveness analysis of COPD screening programs in primary care for high-risk patients in China. npj Primary Care Respiratory Medicine 31:1.
Crossref
Crossref
Ahmed Salem, Heng Zhong, Mafalda Ramos, Mark Lamotte & Hao Hu. (2021) Potential clinical and economic impact of optimised maintenance therapy on discharged patients with COPD after hospitalisation for an exacerbation in China. BMJ Open 11:4, pages e043664.
Crossref
Crossref
Anthony D. D’Urzo, Dave Singh, James F. Donohue & Kenneth R. Chapman. (2019) Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base. Therapeutic Advances in Respiratory Disease 13, pages 175346661985072.
Crossref
Crossref
Han Ni, Soe Moe, Zay Soe, Kay Thi Myint & K Neelakantan Viswanathan. (2018) Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD). Cochrane Database of Systematic Reviews 2018:12.
Crossref
Crossref
A. A. Vizel & I. Yu. Vizel. (2018) 12-Hour fixed-dose combination of andrenergic agonist and cholinergic antagonist in a new administration device: analytical review. Medical Council:15, pages 116-122.
Crossref
Crossref
. (2016) Aclidinium/formoterol good value for money in COPD. PharmacoEconomics & Outcomes News 762:1, pages 9-9.
Crossref
Crossref